# Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

> **NCT01017731** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Cancer
- Solid Tumor

## Interventions

- **BIOLOGICAL:** IMC-1121B
- **DRUG:** Moxifloxacin
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT01017731
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-04
- **Final completion:** 2014-05
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017731, "Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01017731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*